Champions Oncology
CSBR
29 hedge funds and large institutions have $35.6M invested in Champions Oncology in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 10 reducing their positions, and 2 closing their positions.
214% more call options, than puts
Call options by funds: $91K | Put options by funds: $29K
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
4% more funds holding
Funds holding: 28 → 29 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.28% less ownership
Funds ownership: 42.85% → 42.57% (-0.28%)
4% less capital invested
Capital invested by funds: $37M → $35.6M (-$1.4M)
60% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$19.8K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$15.4K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$6.72K |
| 4 |
Renaissance Technologies
New York
|
+$5.69K |
| 5 |
SFG
Steward Financial Group
Colleyville,
Texas
|
+$4.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$181K |
| 2 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$97.2K |
| 3 |
Millennium Management
New York
|
-$71.8K |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
-$48.3K |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$38K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $267 | -$13 | -2 | -4% |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $130 | +$95 | +15 | +250% |
|
28
JP Morgan Chase
New York
| $68 | – | – | – |
|
|
SFI
29
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
| – | -$97.2K | -15,449 | Closed |
|
|
GC
30
Globeflex Capital
San Diego,
California
| – | -$35K | -5,564 | Closed |
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1.26K | -199 | -88% |
|
CSBR Hedge Fund Activity: Q3 2023 in Review
29 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Champions Oncology (CSBR) for Q3 2023, worth a combined $35.6M — down 3.8% from $37M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CSBR positions and 2 closed out — a net gain of 1 holder — while 4 added to existing stakes and 10 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $19.8K. The largest seller was Dimensional Fund Advisors, cutting an estimated $181K.
- 29 institutional investors held Champions Oncology (CSBR) as of Q3 2023, up from 28 in Q2 2023.
- Funds reported $35.6M of Champions Oncology stock for Q3 2023, down 3.8% quarter-over-quarter.
- 3 funds opened new Champions Oncology positions in Q3 2023 and 2 closed out, a net change of +1 holder.
- The largest Champions Oncology buyer in Q3 2023 was UBS Group, an estimated $19.8K added.
- The largest Champions Oncology seller in Q3 2023 was Dimensional Fund Advisors, an estimated $181K sold.
Based on aggregated 13F filings for Q3 2023.